Brimonidine Tartrate is an alpha-2 adrenergic receptor agoinst that is 1000 fold more selective for the alpha-2 adrenoceptor than the alpha-1 adrenoreceptor. This selectivity results in no mydriasis and the absence of vasoconstriction in microvessels associated with human retinal xenografts. It is thought that brimonidine tartrate lowers IOP by enhancing uveoscleral outflow and reducing aqueous humour formation.

Brimonidine Tartrate Ophthalmic Solution is indicated for lowering intraocular pressure in patients with open-angle glucoma or ocular hypertension. The IOP lowering efficacy of Brimonidine Tartrate Ophthamlic Solution diminishes over time in some patients. This loss of effect appers with a variable time of onset in each patient and should be closely monitored.

Although Brimonidine Tartrate Ophthalmic Solution had minimal effect on blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. It should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangiitis obliterans. As with other drugs in this class, it may cause fatigue and/or drowsiness in some patients. Patients who engage in hazardous activities should be cautioned of the potential for a decrease in mental alertness.